Thermo Fisher Scientific(TMO) - 2024 Q1 - Earnings Call Transcript

Turning to our Specialty Diagnostics. In Q1, reported revenue and organic revenue were flat versus the prior year quarter. In Q1, we continued to see strong underlying growth in the core, led by our transplant diagnostics and immunodiagnostics businesses as well as in our healthcare market channel. Q1 adjusted operating income for Specialty Diagnostics increased 5% and adjusted operating margin was 26.5%, which is 120 basis points higher than Q1 2023. During the quarter, we delivered favorable business mix ...